Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 10,333 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Traumatic Arthritis
Interventions: C2a - Taper™ Acetabular System; Device
Lead sponsor: Biomet Orthopedics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 2
States / cities: Cedar Rapids, Iowa • Lexington, Kentucky

Conditions: ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions: Registry, PK microsampling of blood; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Muscular Dystrophy, Duchenne
Interventions: Pentoxifylline; Drug
Lead sponsor: Cooperative International Neuromuscular Research Group; Network
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Rochester, Minnesota • St Louis, Missouri + 2 more

Conditions: Gaucher Disease
Interventions: Taliglucerase alfa; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Decatur, Georgia • New York, New York

Conditions: NOMID, CINCA Syndrome
Interventions: Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 10
States / cities: Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 7 more

Conditions: Iron Overload, Excessive Body Iron Burden
Interventions: R2*-UTE, R2*-GRE, Liver biopsy; Device · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Gainesville, Florida + 5 more

Conditions: Graves' Ophthalmopathy (GO)
Interventions: RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection); Drug · Other
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more

Conditions: Primary Immunodeficiency
Interventions: IgPro20; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 2 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • St. Petersburg, Florida + 7 more

Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Lung Cancer
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 3,087 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Down Syndrome
Interventions: Spatial Ability Experience; Behavioral
Lead sponsor: University of Alabama, Tuscaloosa; Other
Eligibility: 4 Years to 25 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: counseling intervention, educational intervention, survey administration, psychosocial assessment and care, supportive care; Other · Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 8 Years to 120 Years · Female only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort®, Standard Care; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Morehead City, North Carolina

Conditions: Hemophilia B with Inhibitor, Hemophilia B
Interventions: SerpinPC; Drug
Lead sponsor: ApcinteX Ltd; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Tampa, Florida • Greenville, North Carolina

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: decitabine, romidepsin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Down Syndrome
Interventions: Promoting Health through Parent Empowerment and the Activation of Routines, Enhanced Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Months and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Skin Laxity, Muscle Contracture
Interventions: DMA treatment; Device
Lead sponsor: Lumenis Be Ltd.; Industry
Eligibility: 25 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Retinitis Pigmentosa (RP)
Interventions: human retinal progenitor cells; Biological
Lead sponsor: jCyte, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Irvine, California • Los Angeles, California

Conditions: Late Infantile Neuronal Ceroid Lipofuscinosis, Batten Disease
Interventions: Group 1; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 2 Years to 8 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemoglobinopathies, Hemolysis, Iron Deficiency and Overload, Anemias
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year and older
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinitis Pigmentosa
Interventions: Transcorneal Electrical Stimulation using Okustim device; Device
Lead sponsor: Wills Eye; Other
Eligibility: 22 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prader-Willi Syndrome
Interventions: Interview; Other
Lead sponsor: Soleno Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Plymouth, Massachusetts

Conditions: Fuchs' Corneal Endothelial Dystrophy
Interventions: NCI Insertion, Standard Forceps Insertion; Device · Procedure
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Clinical Investigation of the C2a-Taper™ Acetabular System

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

Pentoxifylline in Duchenne Muscular Dystrophy

Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Massive Iron Deposit Assessment

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Blood Collection From Individuals With Lung Disease for Genetic Studies

Assessing Malleability of Spatial Abilities in Down Syndrome

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)

Evaluation of the Immediate Effect and Safety of DMA™ Novel Muscle Stimulation Technology

Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

Collection of Cerebrospinal Fluid in Healthy Children

Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes

Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy Multicenter Study

PWS Outcomes Assessment Study

Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)